Evaluating the Clinical Effectiveness and Safety of Semaglutide in Individuals with Uncontrolled Type 2 Diabetes. Real-World Evidence from Saudi Arabia: The Observational, Multicenter, 15-Month EVOLUTION Study - Concepedia

Concepedia

Publication | Open Access

Evaluating the Clinical Effectiveness and Safety of Semaglutide in Individuals with Uncontrolled Type 2 Diabetes. Real-World Evidence from Saudi Arabia: The Observational, Multicenter, 15-Month EVOLUTION Study

DOI Full Paper Access

14

Citations

27

References

2023

Year

Abdulrahman Alsheikh, Ali Alshehri, Saad Alzahrani, Anwar A. Jammah, Fahad Alqahtani, Metib Alotaibi, Raed Aldahash, Amani Alhozali, Fahad Alsabaan, Mohammed Almehthel,

Diabetes Therapy

Abstract

Semaglutide, administered either by SC injection or orally, provided substantial glycemic and weight-loss benefits in adults with T2DM.

References

	Year	Citations
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition Pouya Saeedi, Inga Petersohn, Belma Malanda, Diabetes Research and Clinical Practice Diabetes EpidemiologyGlobal HealthDiabetesClinical EpidemiologyInternational Health	2019	10K
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide Jesper Lau, Paw Bloch, Lauge Schäffer, Journal of Medicinal Chemistry Albumin AffinityGlycobiologyPeptide SciencePeptide TherapeuticsPharmacotherapy	2015	959
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss Anna Secher, Jacob Jelsing, Arian F. Baquero, Journal of Clinical Investigation Liraglutide UptakeGastrointestinal Peptide HormoneHypothalamic PeptideCell SignalingEnergy Homeostasis	2014	884
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial Richard E. Pratley, Vanita R. Aroda, Ildiko Lingvay, The Lancet Diabetes & Endocrinology Metabolic SyndromeDiabetes ManagementDiabetesPharmacologyClinical Trials	2018	714
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial Christopher Sorli, Shin‐ichi Harashima, George Tsoukas, The Lancet Diabetes & Endocrinology Diabetes ManagementSustain 1DiabetesType 2Clinical Trials	2017	648
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial Andrew Ahmann, Matthew Capehorn, G. Charpentier, Diabetes Care	2017	542
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial Bo Åhrén, Luís Masmiquel, Harish Kumar, The Lancet Diabetes & Endocrinology Diabetes ManagementCardiovascular DiseaseMedicineDiabetesSustain 2	2017	445
Good Practices for Real‐World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR‐ISPE Special Task Force on Real‐World Evidence in Health Care Decision Making Marc L. Berger, Harold C. Sox, Richard J. Willke, Value in Health Family MedicineComparative Effectiveness ResearchHealth SystemsReal‐world Data StudiesGood Practices	2017	444
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial Vanita R. Aroda, Stephen C. Bain, Bertrand Cariou, The Lancet Diabetes & Endocrinology Sustain 4Diabetes ManagementInsulin-naive PatientsInsulin ManagementDiabetes	2017	414
Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10) Matthew Capehorn, Andrei‐Mircea Catarig, Julie Kjærulff Furberg, Diabetes & Metabolism Diabetes ManagementDiabetesPharmacologyType 2Pharmacotherapy	2019	376

Page 1